Dr. Moro,

This may be a good chance to show what you know.

Executive Summary

Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), encourages innovative translational research in the development of quantitative in vivo imaging characterization of image-guided drug delivery (IGDD) in cancer, including characterizations of the target, delivery validation, and therapy response. This FOA will support research in development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer. Validation studies in non-human primates or large animal models and first in human studies directed towards translation of IGDD technology into the clinic will be considered appropriate for this FOA.
Mechanism of Support. This FOA will utilize the Research Project Grant (R01) grant mechanism.
Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Budget and Project Period. Budgets for direct costs of up to $500,000 per year and a project duration of up to five years may be requested. Applicants who request $500,000 or more direct costs per year must follow the instruction in Section IV.6.
Application Research Plan Component Length: The R01 application Research Plan component of the PHS398 (Items 2-5) may not exceed 25 pages, including tables, graphs, figures, diagrams, and charts. See http://grants1.nih.gov/grants/funding/funding_program.htm
Eligible Institutions/Organizations. Institutions/organizations listed in Section III,1.A. are eligible to apply.
Eligible Project Directors/Principal Investigators (PDs/PIs). Include Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
Number of PDs/PIs. More than one PD/PI (i.e., multiple PDs/PIs), may be designated on the application.
Number of Applications. Applicants may submit more than one application, provided that each application is scientifically distinct.
Resubmissions. Applicants may submit a resubmission application, but such application must include an Introduction addressing the previous peer review critique (Summary Statement). See new NIH policy on resubmission (amended) applications (NOT-OD-09-003, NOT-OD-09-016).
Renewals. Applicants may submit a renewal application.
Application Materials. See Section IV.1 for application materials.
General Information. For general information on SF424 (R&R) Application and Electronic Submission, see these Web sites:
SF424 (R&R) Application and Electronic Submission Information: http://grants.nih.gov/grants/funding/424/index.htm
General information on Electronic Submission of Grant Applications: http://era.nih.gov/ElectronicReceipt/
Hearing Impaired. Telecommunications for the hearing impaired are available at: TTY: (301) 451-5936


http://74.125.93.132/search?q=cache:S_bMAqwNBmsJ:grants.nih.gov/grants/guide/pa-files/PA-09-253.html+anticipated+cost+to+image+cancer&cd=1&hl=en&ct=clnk&ie=UTF-8